JLE

Sang Thrombose Vaisseaux

MENU

Thromboembolic complications of membranous nephropathy Volume 34, issue 1, January-February 2022

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

  • Figure 7

  • Figure 8

Tables

Authors
1 Hôpital privé d’Antony, pôle cardiovasculaire interventionnel, 25, rue de la providence, 92160 Antony, France
2 Cabinet de médecine vasculaire, 8, rue Louis Moreau, 91150 Étampes, France
3 Hôpital Henri Mondor, service de néphrologie, 1, rue Gustave Eiffel, 94000 Créteil, France
* Tirés à part

Underlying causes of nephrotic syndrome (NS) include primary and secondary glomerulonephritis where membranous nephropathy (MN) is the most common cause in non-diabetic Caucasian adults over 40 years of age. Although it was recognised as a distinct clinicalpathological entity in 1940 by immunofluorescence and electron microscopy, the pathogenesis and treatment have become more apparent only in the last decade. Discovery of M-type phospholipase A2 receptor (PLA2R) antibodies has given new perspectives in understanding the pathogenesis of the disease process. Increased thromboembolic risk is a well recognized complication of nephrotic syndrome and MN, with variable reported incidence of deep venous thrombosis based on data in case series that mostly were reported more than a decade ago. The pathophysiology of hypercoagulability in the nephrotic syndrome is due to an imbalance of prothrombotic and antithrombotic factors, as well as impaired thrombolytic activities. Despite the well-established risk of venous thromboembolism (VTE) in nephrotic syndrome, the most effective method of VTE prophylaxis is unclear. We discuss the key questions to prophylactically anticoagulate adults with nephrotic syndrome.